Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy

Annals of Hematology

Volumn 92, Issue 12, 2013, Pages 1625-1632

  Wang, Huafeng ^a,b,c   Jin, Jie ^a,b,c   Wang, Yungui ^a,b,c   Huang, Xin ^a,b,c   Huang, Jian ^a,b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Lab of Hematology Diagnose and Treatment   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Chronic myeloid leukemia; Clonal chromosomal abnormality; Nilotinib; Philadelphia negative cells

Indexed keywords

BCR ABL PROTEIN; NILOTINIB;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; MALE; MEDICAL ASSESSMENT; MONOSOMY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TRISOMY 8;

ADULT; AGED; CHROMOSOME ABERRATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84888129177     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1816-z     Document Type: Article

References (25)

1. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330-1340
2. Piccaluga PP, Paolini S, Bertuzzi C, De Leo A, Rosti G (2012) First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. J Blood Med 3:151-156
3. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H (2010) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392-397
4. Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger MW (2003) Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941-1949
5. Deininger MW, Cortes J, Puette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjianaq H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F (2007) The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110:1509-1519
6. Fabarius A, Haferlach C, Müller MC, Erben P, Lahaye T, Giehl M, Frank O, Seifarth W, Hehlmann R, Hochhaus A (2007) Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 92:834-837
7. De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG (2007) Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 110(8):3086-3087
8. Zeidan A, Kakati S, Anderson B, Barcos M, Wetzler M (2007) Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genet Cytogenet 176:169-171
9. Baldazzi C, Luatti S, Marzocchi G, Stacchini M, Gamberini C, Castagnetti F, Palandri F, Rosti G, Baccarani M, Testoni N (2009) Emergence of clonal chromosomal abnormalities in Philadelphia-negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res 33:218-220
10. Kim TD, Dörken B, le Coutre P (2008) Nilotinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol 1(1):29-39
11. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834-1839
12. ISCN (2005) An International System for Human Cytogenetic Nomenclature. In: Mitelman F, editor. Basel, Switzerland:S. Karger
13. Larsson N, Billström R, Lilljebjörn H, Lassen C, Richter J, Ekblom M, Fioretos T (2010) Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. Cancer Genet Cytogenet 199:89-95
14. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, Van den Akker J, Leonard C, N'Guyen Khac F, Mugneret F, Viguié F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M, France Intergroupe pour la Leucemie Myeloide Chronique (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340-1346
15. Paulsson K, Sall T, Fioretos T, Mitelman F, Johansson B (2001) The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2:160-165
16. Kovitz C, Kantarjian HM, Garcia-Manero G, Abruzzo LV, Cortes J (2006) Myelodysplastic syndrome and acute leukemia after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108:2811-2813
17. Athanasiadou A, Lalayanni C, Papaioannou G, Gaitatzi M, Fassas A, Anagnostopoulos A (2008) Novel chromosomal aberration in Philadelphia-negative cells of a patient with chronic myelogenous leukemia treated with dasatinib. Leuk Lymphoma 49:1012-1013
18. Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT (2003) The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 31:702-707
19. Fabarius A, Giehl M, Frank O, Spiess B, Zheng C, Müller MC, Weiss C, Duesberg P, Hehlmann R, Hochhaus A, Seifarth W (2007) Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. Br J Haematol 138:369-373
20. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814-817
21. Lin Y, Bruyere H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, SutherlandHJ TCL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL (2006) Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 170:16-23
22. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Working Party GIMEMACML (2009) Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 114:4933-4938
23. Quintas-Cardama A, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Faderl S, Konopleva M, Wierda WG, Burton E, Cortes JE (2011) Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP). Blood 118:454
24. Bakalova R, Zhelev Z, Spasov L (2012) Nilotinib versus imatinib: molecular mechanism(s) of its better efficacy. Cancer 118:5180-5181
25. Eiring AM, Khorashad JS, Morley K, Deininger MW (2011) Advances in the treatment of chronic myeloid leukemia. BMC Med 9:99